top of page

Skye Bioscience's CEO Punit Dhillon discusses next generation CB1 inhibition for obesity, and flags how key data from competitor Novo coming this quarter could impact the class

  • Aug 30, 2024
  • 1 min read

He describes Skye's CB1 program and the rationale for targeting fat tissue, and why today's versions of these therapies could be better and more tolerable than previous generations. Plus, the path forward and how competitor data will be public soon.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page